AC Immune SA (ACIU) Downgraded by Zacks Investment Research to Sell
Zacks Investment Research downgraded shares of AC Immune SA (NASDAQ:ACIU) from a hold rating to a sell rating in a research note issued to investors on Thursday morning.
According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “
Separately, Credit Suisse Group set a $18.00 price target on shares of AC Immune SA and gave the company a buy rating in a report on Wednesday, July 19th.
Shares of AC Immune SA (NASDAQ:ACIU) opened at $10.61 on Thursday. AC Immune SA has a 52 week low of $6.03 and a 52 week high of $16.60.
ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/ac-immune-sa-aciu-downgraded-by-zacks-investment-research-to-sell/1714980.html.
A number of large investors have recently bought and sold shares of the business. Wells Fargo & Company MN purchased a new position in AC Immune SA during the 3rd quarter valued at about $111,000. Janney Montgomery Scott LLC acquired a new stake in shares of AC Immune SA during the 3rd quarter worth about $134,000. Goldman Sachs Group Inc. acquired a new stake in shares of AC Immune SA during the 2nd quarter worth about $127,000. Cohen Lawrence B acquired a new stake in shares of AC Immune SA during the 2nd quarter worth about $297,000. Finally, Belpointe Asset Management LLC acquired a new stake in shares of AC Immune SA during the 3rd quarter worth about $571,000. Hedge funds and other institutional investors own 19.21% of the company’s stock.
About AC Immune SA
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related companies with Analyst Ratings Network's FREE daily email newsletter.